Thumbnail Image
Publication

Durvalumab impact in the treatment strategy of stage III non-small cell lung cancer (NSCLC): an EORTC Young Investigator Lung Cancer Group Survey

Levra, MG
; 
Benet, J
; 
Hasan, B
; 
Berghmans, T
; 
Bruni, A
; 
Dingemans, A
; 
Levra, NG
; 
Edwards, J
; ; 
Girard, N
... show 10 more
Citations
Altmetric:
Abstract
Authors
Levra, MG
Benet, J
Hasan, B
Berghmans, T
Bruni, A
Dingemans, A
Levra, NG
Edwards, J
Faivre-Finn, Corinne
Girard, N
Gobbini, E
Greillier, L
Hendriks, L
Lantuejoul, S
Levy, A
Novello, S
O'Brien, M
Reck, M
Pochesci, A
Menis, J
Besse, B
Affiliation
CHU Grenoble, La Tronche/FR,
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Levra MG, Benet J, Hasan B, Berghmans T, Bruni A, Dingemans AM, et al. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey. Journal of Thoracic Oncology. 2019;14(10):S277-S8.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622537
Embedded videos